Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

To address this problem, antibody engineers introduced a serine-to-proline substitution that made the middle hinge region more like that found in IgG1 (ref. 7). This not only gave a more ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...